Money Movers: HIT, SEPN, ALUR, LUCY, PRSO – Biotech, Healthcare, AI & Weight Loss Innovators Lead Momentum Surge – More Stocks InsideToday’s pre-market spotlight highlights a powerful mix of emerging growth companies driving innovation across key sectors including AI-powered Insurtech, mmWave wireless connectivity, smart wearables, clinical-stage biotech, and advanced weight loss solutions. From Health In Tech’s (
NASDAQ: HIT) disruptive insurance platform to Peraso’s (
NASDAQ: PRSO) wireless technology milestone, Allurion’s (
NASDAQ: ALUR) FDA-ready program, Septerna’s (
NYSE: SEPN) GPCR-based therapeutics, Quoin’s (
NASDAQ: QNRX) progress in rare skin disease treatment and Innovative Eyewear’s (
NASDAQ: LUCY) Smart Branded eyewear, these companies represent pivotal trends shaping the market in 2025. As investors seek early exposure to transformative technologies, these pre-market movers warrant close attention.
Skinvisible Reports Licensee Success in Netherton Syndrome Clinical StudiesLAS VEGAS, NV / ACCESS Newswire / January 23, 2025 / Skinvisible Pharmaceuticals, Inc. ("Skinvisible" or "the Company"), (OTCQB:SKVI), an innovative topical and transdermal pharmaceutical research and development company, with proprietary Invisicare® drug delivery technology, today announces significant achievements in 2024 and 2025, through its licensee Quoin Pharmaceuticals' progress in Netherton Syndrome treatment.
Quoin Pharmaceuticals' Commitment to Delivering Treatment for Netherton Syndrome Patients and Creating Value for ShareholdersSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
A Pivotal Year Ahead for Quoin PharmaceuticalsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Quoin Pharmaceuticals: Strategically Building For Future SuccessSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Skinvisible Announces First Invisicare Delivery Technology Product to Receive U.S. FDA Acceptance of Investigational New DrugLAS VEGAS, NV / ACCESSWIRE / June 6, 2022 / Skinvisible, Inc. ("Skinvisible") (OTCQB:SKVI), is pleased to announce that its licensee Quoin Pharmaceuticals, Inc. ("Quoin") (
NASDAQ:QNRX), has received U.S. FDA acceptance of its Investigational New Drug (IND) application for its licensed formulation which uses Skinvisible's Invisicare® proprietary drug delivery technology. The topical formulation "QRX003" was developed to treat Nethertons Syndrome, a debilitating hereditary disorder that affects the skin, hair and the immune system. There currently is no cure or approved treatment for Netherton Syndrome.
Quoin Pharmaceuticals Targeting Regulatory Approvals for Lead Candidate for Netherton Syndrome in 2024Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Changing Lives, Delivering Value: Quoin Pharmaceuticals is Making the Balancing Act Look EasySearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Quoin Pharmaceuticals Poised for Rapid Commercialization of Promising PipelineSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
